Sun finally shines on Horizant, as FDA OK’s GSK-XenoPort RLS drug
This article was originally published in Scrip
Investors jumped for joy on 7 April on the news that GlaxoSmithKline and its partner XenoPort finally gained the US FDA's blessing for their extended-release gabapentin enacarbil product Horizant (XP13512/GSK1838262) as a treatment for adults with moderate-to-severe primary restless legs syndrome (RLS) – an approval that came after a long and winding road.
You may also be interested in...
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.